A Delaware man is the first to take legal action against the manufacturer of a batch of a bone graft product that’s reported to have caused patients to contract tuberculosis post-surgery.
The lot of FiberCel, the product made by Delaware-based biotechnology company Aziyo Inc., included 154 units distributed across 20 states, and the company has recognized at least four patients who received FiberCel from that lot have developed tuberculosis.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
